GSK3A and fragile X syndrome: The improved insulin sensitivity in diet-induced obese mice treated with GSK3α inhibitor from our result, together with its beneficial effects on mouse models of acute myeloid leukemia and fragile X syndrome (McCamphill et al., 2020; Wagner et al., 2018), advocates the therapeutic potential of isoform-specific inhibition of GSK3α in ameliorating metabolic disorders or cancers.